Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

This study has been completed.

Study NCT00343551 Information provided by Novartis

First Received: June 22, 2006 Last Updated: July 15, 2008 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	January 2007 (Final data collection date for primary outcome measure)